Neura.net: Perspectives on CNS Disease Management
Member Login  |  Site Map  |  Disclaimer  |  Contact  |  Bookmark
Advanced Search
Text Size
 |  Tuesday, September 07, 2010 
Home
 
 
Home > Neura > Benign Multiple Sclerosis > Essential Tremor > References
References
 

1. Benito-León J. How common is essential tremor? Neuroepidemiology. 2009;32:215-216. [PubMed]

2. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13:5-10. [PubMed]

3. Sullivan KL, Nauser RA, Zesiewicz TA. Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist. 2004;10:250-258. [PubMed]

4. Benito-León J, Bermego-Pareja F, Morales JM, Vega S, Molina JA. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord. 2003;18:389-394. [PubMed]

5. Benito-León J, Bermego-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM. Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18:267-274. [PubMed]

6. Thawani SP, Schupf N, Louis ED. Essential tremor is associated with dementia. Prospective population-based study in New York. Neurology. 2009;73:621-625. [PubMed]

7. Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nature Clin Pract. 2006;12:666-678. [PubMed]

8. Kim J-S, Song I-U, Shim T-S, et al. Cognitive impairment in essential tremor without dementia. J Clin Neurol. 2009;5:81-84. [PubMed]

9. Louis ED, Benito-Leon J, Bermejo-Pareja F; Neurological Disorders in Central Spain (NEDICES) Study Group. Self-reported depression and antidepressant medication use in essential tremor: cross-sectional and prospective analyses in a population-based study. Eur J Neurol. 2007;14(10):1138- 1146. [PubMed]

10. Louis ED, Bromley SM, Jurewicz EC, Watner D. Olfactory dysfunction in essential tremor: a deficit unrelated to disease duration or severity. Neurology. 2002;59:1631-1633. [PubMed]



21. Louis ED. Etiology of essential tremor: should we be searching for environmental causes? Mov Disord. 2001;16:822-829. [PubMed]

22. Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology. 2008;31:139-149. [PubMed]

23. Benito-León J, Alvarez-Linera J, Hernández-Tamames JA, Alonso-Navarro, Jiménez- Jiménez F, Louis ED. Brain structural changes in essential tremor: voxel-based morphometry at 3-Tesla. J Neurol Sci. 2009;289:138-142. [PubMed]

24. Schnitzler A, Münks, Butz M, Timmermann L, Gross J. Synchronized brain network associated with essential tremor as revealed by magnetoencephalography. Mov Disord. 2009;24:1629-1635. [PubMed]

25. Louis ED, Vonsattel JP, Honig LS, Ross GW, Lyons KE, Pahwa R. Neuropathological changes in essential tremor. Neurology. 2006;66:1756- 1759. [PubMed]

26. Louis ED, Vonsattel JP, Honig LS. Essential tremor associated with pathologic changes in the cerebellum. Arch Neurol. 2006;63:1189-1193. [PubMed]

27. Louis ED, Faust PL, Vonsattel J-P, et al. Torpedoes in Parkinson’s disease, Alzheimer’s disease, essential tremor, and control brains. Mov Disord. 2009;24:1600-2605. [PubMed]

28. Louis ED, Honig LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study. Arch Neurol. 2005;62:1004-1007. [PubMed]

29. Frisina PG, Tse W, Hälbig TD, Libow LS. The pattern of cognitive-functional decline in elderly essential tremor patients: an exploratory-comparative study with Parkinson’s and Alzheimer’s disease patients. J Am Med Dir Assoc. 2009;10:238-242. [PubMed]

30. Louis ED. Essential tremor as a neuropsychiatric disorder. J Neurol Sci. 2009;289:144-148. [PubMed]


31. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder. How are we misdiagnosing essential tremor? Arch Neurol. 2006;63:1100-1104. [PubMed]

32. Antonini A, Berto P, Lopatriello S, Tamma F, Annemans L, Chambers M. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson’s disease in Italy. Mov Dis. 2008;23:2202-2209. [PubMed]

33. Isais IU, Canesi M, Benti R, et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun. 2008;29:349-353. [PubMed]

34. Hawkes CH, Shephard BD, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:436-446. [PubMed]

35. Elble RJ, Deuschl G. An update on essential tremor. Curr Neurol Neurosci Rep. 2009;9:273-277. [PubMed]

36. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008-2020. [PubMed]

37. Pahwa R, Lyons KE. Essential tremor: differential diagnosis and current therapy. Am J Med. 2003;115:134-142. [PubMed]

38. Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66:672-677. [PubMed]

39. Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2007;22:1660-1663. [PubMed]

40. Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord. 2009;24:437-440. [PubMed]


41. Lyons KE, Pahwa R. Pharmacotherapy of essential tremor. An overview of existing and upcoming agents. CNS Drugs. 2008;22:1037-1045. [PubMed]

42. Lyons KE, Pahwa R, Comella CL, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26:461-481. [PubMed]

43. Gunal DI, Afsar N, Bekiroglu N, et al. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci. 2000;21:315-317. [PubMed]

44. Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987;37:471-474. [PubMed]

45. Thompson C, Lang A, Parkes JD, et al. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol. 1984;7:83-88. [PubMed]

46. Koller WC. A new drug for treatment of essential tremor? Time will tell. Mayo Clin Proc. 1991;66:1085-1087. [PubMed]

47. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addiction Biol. 2006;11:117-125. [PubMed]

48. Louis ED, Benito-León J, Bermejo-Pareja F. Population-based study of baseline ethanol consumption and risk of incident essential tremor. J Neurol Neurosurg Psychiatry. 2009;80:494-497. [PubMed]

49. Antonini A, Isaias I. Imaging evidence supports a link between essential tremor and Parkinson’s disease. Nucl Med Comm. 2009;30:93-94. [PubMed]

50. Hedera P, Fang JY, Phibbs FT, Cooper MK, Davis TL. Positive family history of essential tremor influences the motor phenotype of Parkinson’s disease. Mov Disord. 2009;24(suppl 1):S527. [PubMed]

51. Simoes RM, Constantino A, Houghton D, Louis E, Litvan I. Are there clinical features associated with the development of Parkinson’s disease in essential tremor? Mov Disord. 2009;24(suppl 1):S518.

52. Benito-León J, Louis ED, Bermejo-Pareja FB, on behalf of the Neurological Disorders in Central Spain (NEDICES) Study Group. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80:423-425. [PubMed]



   
        Add to Google Add to My Yahoo!
Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients, click here. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.